Literature DB >> 11887866

Encapsulating peritoneal sclerosis in Japan: prospective multicenter controlled study.

H Kawanishi1.   

Abstract

OBJECTIVE: Encapsulating peritoneal sclerosis (EPS) is recognized as a serious complication of peritoneal dialysis. The aim of this study was to determine the incidence, clinical features, and variation in mortality rates for EPS.
DESIGN: A prospective multicenter design was used, in which peritoneal dialysis patients were pre-registered by facilities across Japan and the incidence of EPS was observed in the registrants. The registrants were followed for a total of 4 years to accurately observe the onset of EPS.
RESULTS: As of April 1999, 2216 peritoneal dialysis patients from 64 facilities were registered. By the end of March 2001, 332 patients had dropped out, and 17 of the dropouts had developed SEP. The incidence was 0.77%. After excluding 110 patients who died, the incidence in 2106 patients was 0.81%. The incidence of EPS increased with the duration of peritoneal dialysis. Of the 17 patients with EPS, 12 developed the condition after discontinuing peritoneal dialysis and changing to hemodialysis. During the 2-year survey period, 6 of the 17 EPS patients died. The interval from onset to death was 10.8 +/- 5.8 months (range: 3-19.5 months).
CONCLUSIONS: From this prospective multicenter study, the current incidence of EPS is 0.77% (0.81% when dropout owing to death is censored). After a follow-up of 2 years, we conjecture that the incidence of EPS will increase. The incidence, etiology, and prognosis of EPS will be further clarified by periodic observation of dropouts until the end of March 2003.

Entities:  

Mesh:

Year:  2001        PMID: 11887866

Source DB:  PubMed          Journal:  Perit Dial Int        ISSN: 0896-8608            Impact factor:   1.756


  9 in total

1.  No need for an "expiry date" in chronic peritoneal dialysis to prevent encapsulating peritoneal sclerosis.

Authors:  Guido Garosi; Dimitrios G Oreopoulos
Journal:  Int Urol Nephrol       Date:  2009-12       Impact factor: 2.370

Review 2.  Encapsulating peritoneal sclerosis: the state of affairs.

Authors:  Mario R Korte; Denise E Sampimon; Michiel G H Betjes; Raymond T Krediet
Journal:  Nat Rev Nephrol       Date:  2011-08-02       Impact factor: 28.314

3.  Encapsulating peritoneal sclerosis in the new millennium: a national cohort study.

Authors:  Michaela C Brown; Keith Simpson; Jan J Kerssens; Robert A Mactier
Journal:  Clin J Am Soc Nephrol       Date:  2009-06-18       Impact factor: 8.237

4.  Encapsulating peritoneal sclerosis: case series from a university center.

Authors:  Kyung-Deuk Hong; Ji Hea Bae; Yun-Jin Jang; Hee-Yeon Jung; Jang-Hee Cho; Ji-Young Choi; Chan-Duck Kim; Yong-Lim Kim; Sun-Hee Park
Journal:  Korean J Intern Med       Date:  2013-08-14       Impact factor: 2.884

Review 5.  Inflammation and the peritoneal membrane: causes and impact on structure and function during peritoneal dialysis.

Authors:  Gilberto Baroni; Adriana Schuinski; Thyago P de Moraes; Fernando Meyer; Roberto Pecoits-Filho
Journal:  Mediators Inflamm       Date:  2012-03-25       Impact factor: 4.711

6.  Incidence and outcome of encapsulating peritoneal sclerosis.

Authors:  Michaela C Petrie; Jamie P Traynor; Robert A Mactier
Journal:  Clin Kidney J       Date:  2016-06-20

7.  Case report: acute bowel obstruction with an isolated transition point in peritoneal dialysis patients; a presentation of encapsulating peritoneal sclerosis?

Authors:  Sassan Ghazan-Shahi; Joanne M Bargman
Journal:  BMC Nephrol       Date:  2016-01-05       Impact factor: 2.388

8.  Encapsulating Peritoneal Sclerosis in Long-Termed Peritoneal Dialysis Patients.

Authors:  Heng-Jung Hsu; Shih-Ying Yang; I-Wen Wu; Kuang-Hung Hsu; Chiao-Yin Sun; Chun-Yu Chen; Chin-Chan Lee
Journal:  Biomed Res Int       Date:  2018-11-13       Impact factor: 3.411

Review 9.  Encapsulating Peritoneal Sclerosis: Pathophysiology and Current Treatment Options.

Authors:  Rajesh M Jagirdar; Andreas Bozikas; Sotirios G Zarogiannis; Maria Bartosova; Claus Peter Schmitt; Vassilios Liakopoulos
Journal:  Int J Mol Sci       Date:  2019-11-16       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.